Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 13, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function.

Satoru Senju1, Hirofumi Suemori, Hitoshi Zembutsu

  • 1Department of Immunogenetics, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan. senjusat@gpo.kumamoto-u.ac.jp

Stem Cells (Dayton, Ohio)
|August 11, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.

Cancer letters·2026
Same author

Corrigendum to "Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms" [Vaccine 68 (2025) 127942].

Vaccine·2026
Same author

Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms.

Vaccine·2025
Same author

NN15-017 promotes human pluripotent stem cell proliferation and generation.

Regenerative therapy·2025
Same author

Acetylation of lysine 49 on Ctnnb1 drives naïve pluripotency in murine stem cells by modulating Nanog function.

PNAS nexus·2025
Same author

Inhibition of N-myristoyltransferase in pluripotent stem cells promotes the naive state in mice and elicits trophectoderm and primitive endoderm markers in humans.

Stem cell reports·2025

Genetically engineered dendritic cells (DCs) from human embryonic stem cells (ESCs) show promise for immune therapy. These engineered cells can present antigens and modulate T cell responses, offering a novel therapeutic approach.

Area of Science:

  • Immunology
  • Stem Cell Biology
  • Genetic Engineering

Background:

  • Dendritic cells (DCs) are crucial for initiating immune responses.
  • Antigen-specific immune therapies aim to precisely target immune cells.
  • Embryonic stem cells (ESCs) offer a renewable source for cell-based therapies.

Purpose of the Study:

  • To generate and characterize dendritic cells (DCs) derived from human embryonic stem cells (ESCs).
  • To genetically modify these ESC-derived DCs (ES-DCs) for enhanced therapeutic potential.
  • To evaluate the immune stimulatory and modulatory functions of genetically modified ES-DCs.

Main Methods:

  • Generation of human ES-DCs from ESCs.
  • Genetic modification of ES-DCs using non-viral plasmid introduction into undifferentiated ESCs via electroporation.

More Related Videos

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Related Experiment Videos

Last Updated: Jul 13, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

  • Characterization of ES-DC surface markers and T cell stimulatory capacity.
  • Assessment of antigen presentation and T cell response modulation by engineered ES-DCs.

    • Main Results:

    • Human ES-DCs express characteristic DC surface markers and stimulate allogeneic T lymphocytes.
    • Genetically modified ES-DCs effectively process and present antigens via HLA class II.
    • Non-viral genetic modification of ES-DCs was successfully achieved.
    • Engineered ES-DCs expressing antigen-presenting vectors stimulated antigen-specific T cells without exogenous antigen.
    • Forced expression of programmed death-1-ligand-1 in ES-DCs reduced T cell proliferation.

    Conclusions:

    • ES-DC technology provides a novel platform for developing antigen-specific immune therapies.
    • Non-viral genetic modification of ES-DCs is feasible and effective.
    • Genetically modified ES-DCs demonstrate potential for modulating immune responses for therapeutic benefit.
    • This technology is also applicable to nonhuman primate ESCs, suggesting broader translational potential.